CIBC Asset Management
VIR icon

CIBC Asset Management’s Vir Biotechnology VIR Stock Holding History

CIBC Asset Management’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-10,006
Closed -$57.1K – 1431
2025
Q3 		$57.1K Hold
10,006
– – ﹤0.01% 1225
2025
Q2 		$50.4K Hold
10,006
– – ﹤0.01% 1205
2025
Q1 		$64.8K Sell
10,006
-126
-1% -$1.12K ﹤0.01% 1157
2024
Q4 		$74.4K Buy
+10,132
New +$79.9K ﹤0.01% 1191
2022
Q1 		– Sell
-5,206
Closed -$218K – 1598
2021
Q4 		$218K Sell
5,206
-7
-0.1% -$274 ﹤0.01% 1335
2021
Q3 		$227K Buy
5,213
+514
+11% +$22.3K ﹤0.01% 1253
2021
Q2 		$222K Hold
4,699
– – ﹤0.01% 1215
2021
Q1 		$241K Buy
+4,699
New +$253K ﹤0.01% 1111

Other funds holding VIR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GP
GSK plc London $602M AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

CIBC Asset Management's VIR Position: Q4 2025 in Review

CIBC Asset Management sold out of Vir Biotechnology (VIR) in Q4 2025, closing a stake of 10,006 shares — an estimated $57.1K sold.

CIBC Asset Management first reported a position in VIR in Q1 2021 and held it in 8 quarters. The position peaked at $241K in Q1 2021. 218 funds tracked by Wall St. Rank hold VIR as of Q4 2025.

  • CIBC Asset Management reported no remaining Vir Biotechnology position as of Q4 2025 after selling out during the quarter.
  • CIBC Asset Management sold 10,006 Vir Biotechnology shares in Q4 2025, an estimated $57.1K.
  • CIBC Asset Management first reported a position in Vir Biotechnology in Q1 2021 and held it in 8 quarters.
  • CIBC Asset Management's Vir Biotechnology position peaked at $241K in Q1 2021.
  • 218 funds tracked by Wall St. Rank held Vir Biotechnology as of Q4 2025.

Based on CIBC Asset Management's 13F filing for Q4 2025, filed 10 Feb 2026.